← Back to headlines
Syndax Targets $10B Opportunity with Revuforj and Niktimvo
Syndax Pharmaceuticals is signaling an expansion of Revuforj's market share and targeting a $10 billion addressable opportunity while ramping up Niktimvo.
27 Feb, 03:48 — 27 Feb, 03:48
ℹOnly 1 source covers this story
